Novartis Slovakia’s Marianthi Psaha discusses the upcoming shift in Slovakia’s healthcare landscape, the importance of a healthy dialogue between the public and private sectors, and the responsibility of the pharma industry to continuously strive for the highest standards of compliance, integrity and performance.
You have been Country President for Slovakia and CPO Head for just under a year and a half; what have been your main achievements in that period and what are your priorities moving forward?
"Slovakia has a big potential to be a leading example across the EU countries because of the country size, its ability to run pilots, analyses & real outcomes measurements."
